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The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by
surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated
with induction chemoradiotherapy consisting of cisplatin (40mgm
 2) and docetaxel (40mgm
 2) given on days 1, 8, 29 and 36 plus
concurrent thoracic irradiation at a dose of 40–60Gy (2Gyfraction
 1day
 1). Surgical resection was performed within 6 weeks after
completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients
(91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological
complete response were obtained in 14 (64%) and five (23%) patients, respectively. With a median follow-up period of 32 months,
the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year
overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with
standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in
patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.
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Since the majority of patients with locally advanced non-small-cell
lung cancer (LA-NSCLC) develop distant metastases, the treatment
outcomes of patients receiving surgery or radiotherapy alone are
extremely poor. In previous reports, 5-year survival rates of LA-
NSCLC patients undergoing locoregional treatment alone ranged
from 5 to 15% (Pearson et al, 1982; Martini and Flehinger, 1987;
Mountain, 1988; Shields, 1990; Cox et al, 1991). Therefore, a
combined modality approach to control both local tumour and
distant micrometastasis is required to improve the treatment
outcome. A variety of multimodality therapies that include
chemotherapy, surgery and/or radiotherapy have recently been
assessed in clinical trials. Use of postoperative chemotherapy or
radiotherapy has not shown an apparent survival benefit to date
(The Lung Cancer Study Group, 1981; Pisters et al, 1994; Keller
et al, 2000). Although Le Chevalier et al (2003) recently reported a
statistically significant prolongation of survival in a large-scale
randomised study of postoperative chemotherapy, the advantage
was extremely limited. On the other hand, preoperative che-
motherapy resulted in a definite survival advantage in a few
randomised trials comparing preoperative chemotherapy plus
surgery with surgery alone in LA-NSCLC patients (Rosell et al,
1994; Roth et al, 1994). Local recurrence rates in these trials were
considerably high, however. For example, Rosell et al (1994)
reported a local recurrence rate of 54% in patients who received
preoperative mitomycin, ifosfamide and cisplatin. Similarly, in our
previous study of preoperative cisplatin and irinotecan chemother-
apy, the local recurrence rate was 33% overall and 50% in patients
being treated for disease relapse (Date et al, 2002). Then, we
considered that further prolongation of survival might be obtained
by improvement of local control, adding concurrent thoracic
irradiation to induction chemotherapy. In several recent reports,
preoperative chemoradiotherapy in patients with LA-NSCLC was
shown to be feasible and effective, although the new drugs
developed in the 1990s such as irinotecan and docetaxel were not
included (Albain et al, 1995; Choi et al, 1997; Eberhardt et al, 1998;
Thomas et al, 1999). We have already confirmed the feasibility and
effectiveness of concurrent chemoradiotherapy using cisplatin and
docetaxel in patients with unresectable LA-NSCLC (Kiura et al,
2003), whereas a combination of cisplatin, irinotecan and
concurrent thoracic irradiation has been reported to be toxic
and unacceptable (Yokoyama et al, 1996). Based on these results,
the present study was planned to assess the feasibility and
effectiveness of this chemoradiotherapy as preoperative treatment
in patients with LA-NSCLC.
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lPATIENTS AND METHODS
Patient selection
Previously untreated patients with histologically confirmed stage
IIIA or IIIB NSCLC, with measurable disease, were eligible for the
study. In this study, a mediastinal lymph node X10mm along the
short axis by CT scan was defined as a metastatic lymph node. The
other inclusion criteria were age p75 years, Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0–2 (Oken
et al, 1982), and adequate functional reserves of bone marrow
(leucocyte count 44000ml
 1, platelet count 4100000ml
 1), liver
(serum bilirubin level o1.5mgdl
 1, aspartate aminotransferase
and alanine aminotransferase levels (AST/ALT) o2 times the
upper normal limit), kidney (serum creatinine level o1.5mgdl
 1,
creatinine clearance 460mlmin
 1) and lung (arterial oxygen
pressure (PaO2) 460Torr). Patients with concomitant malignan-
cies, supraclavicular lymph node involvement, or malignant
pleural or pericardial effusion were excluded from the study.
Written informed consent was obtained from all patients.
Evaluations
Staging procedures included medical history and physical
examination, complete blood cell counts (CBC), standard blood
chemistry profile, 24-h urine creatinine clearance (Ccr), electro-
cardiogram, chest radiography, computed tomography (CT) scans
of the chest and upper abdomen, magnetic resonance imaging
(MRI) of the brain, fibre optic bronchoscopy and radionuclide
bone scan. Magnetic resonance imaging of the chest was required
if mediastinal invasion was suspected.
During treatment, CBC was repeated two to three times a week,
and blood chemistry tests, Ccr evaluations and chest radiograph
were repeated at least once a week. Chest CT scans were repeated
after each chemotherapy course. After completion of combined
modality treatment, each patient was restaged with all tests used
for the initial work-up, and followed monthly with chest
radiographs. CT scans were repeated every 3 months.
Treatment plan
Chemotherapy was administered on days 1, 8, 29 and 36. Patients
were premedicated with dexamethasone (8mg) and granisetron
(3mg) or ondansetron (4mg) immediately prior to cisplatin
administration. Cisplatin 40mgm
 2 diluted in 300ml of physio-
logical saline was given as a 1-h i.v. infusion, followed by docetaxel
40mgm
 2 dissolved in 500ml of physiological saline as a 1-h i.v.
infusion. Patients then received hydration with 2000ml of
physiological saline. If leucocyte count was less than 3000ml
 1 or
platelet count less than 100000ml
 1 on day 29, chemotherapy was
postponed until recovery. No dose attenuations were planned for
reductions in leucocyte or platelet counts on days 8 or 36.
Radiotherapy was started on the first day of chemotherapy using a
linear accelerator (6–10MeV). A total radiation dose of 40Gy was
planned with conventional fractionation (2Gyday
 1). Dose
escalation of radiotherapy was allowed for poorly responding
tumours. The original volume included the site of primary tumour
with a margin of 2cm around the mass and the ipsilateral hilum,
and the whole width of the mediastinum with a margin of 1cm
around the radiographically visible region of involvement extend-
ing inferiorly to 3cm below the carina or 2cm below the
radiographically demonstrated tumour mass. The original volume
was treated with an anterior–posterior parallel-opposed pair of
portals at doses of 40 or 46Gy. For poor responding patients, an
additional 20Gy dose was administered to the boost volume,
including the sites of primary tumour and involved lymph nodes.
The boost volume was treated with a pair of oblique fields to keep
cumulative radiation dose to the spinal cord at less than 46Gy.
Following induction chemoradiotherapy, patients were evalu-
ated for response based on a chest radiograph and CT scans.
Patients without progressive disease were to have surgery within 6
weeks of completing induction therapy. The surgical procedure
was determined on the basis of disease extent before induction
treatment. Lobectomy was preferred; however, bilobectomy, sleeve
resection, or pneumonectomy was performed in cases requiring
those procedures because of primary tumour invasion. Resection
with reconstruction of the chest wall was performed if necessary.
The bronchial stump was covered with intercostal muscle pedicle.
Postoperative treatment was left to the physician’s discretion.
Usually, if apparent residual tumour was left or viable cells were
found in the surgically resected specimens, further chemotherapy
was given.
Response, survival and toxicity assessments
Response was assessed using ECOG criteria (Oken et al, 1982),
with some modification, as follows: complete response (CR),
disappearance of all tumour at the end of induction therapy;
partial response (PR), a X50% reduction in the sum of the
products of two perpendicular dimensions of all measurable
lesions; stable disease (SD), a o50% reduction and o25% increase
in the sum of the products of two perpendicular dimensions of all
measurable lesions; progressive disease (PD), a X25% enlarge-
ment of tumour lesion or the appearance of any new lesions.
Survival was assessed on an ‘intent-to-treat’ basis, with survival
time defined as the period from initiation of chemoradiotherapy to
death or the last follow-up evaluation. The survival curve was
calculated by the Kaplan and Meier (1958) method. Toxicity was
assessed by the National Cancer Institute-Common Toxicity
Criteria (NCI-CTC) (NCI-CTC version 2.0, 1998). Statistical
analyses were performed using an SPSS Base System and Advanced
Statistics Program (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Between August 1998 and August 2001, 22 patients with stage IIIA
or stage IIIB NSCLC were treated with this combined modality
treatment. The baseline patient characteristics are listed in Table 1.
Median age was 60 years and PS was 0 or 1 in all patients. In all, 18
patients had N2 disease, of whom nine had histologically proven
N2 disease by mediastinoscopy or transbronchial needle aspiration
biopsy. One patient had N3 disease in the contralateral mediastinal
lymph node. Seven patients had T4 disease consisting of aortic
invasion in three patients, pulmonary artery invasion in three, and
mediastinal invasion in one, which were confirmed by enhanced
chest MRI.
Induction therapy: response and toxicities
Out of 22 evaluable patients, 11 completed the planned chemor-
adiotherapy treatment. Chemotherapy dose was modified due to
toxicity in 11 patients. Docetaxel dose was reduced on days 29 and
36 in four patients. Four patients did not receive chemotherapy on
day 36 due to neutropenia in three patients and diarrhoea in one.
In three patients, chemotherapy was omitted on both days 29 and
36 and only radiation therapy was accomplished, because of
anaphylactic reaction to docetaxel, paralytic ileus and patient
refusal in one patient each. The total radiation dose was 40Gy in 10
patients, 46Gy in nine and 60Gy in three. Clinical response to
induction therapy was PR in 16 patients (73%) and SD in six
(27%). Toxicities experienced during induction therapy are listed
in Table 2. Grades 3 and 4 leukopenia and neutropenia were each
observed in 13 patients; however, no febrile neutropenia occurred.
Nonhaematological toxicities were primarily gastrointestinal
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congestive heart failure with atrial fibrillation, paralytic ileus and
anaphylactic reaction to docetaxel in one patient each.
Surgery and pathologic response
Two of 22 patients did not undergo surgical resection because of
congestive heart failure (n¼1) and patient refusal (n¼1). For 20
patients who had surgery, the median time from the end of
induction therapy to surgery was 37 days (range, 25–59 days).
Surgical procedures included lobectomy in 16 patients, sleeve
lobectomy in two and bilobectomy and pneumonectomy in one
each. One patient who had contralateral mediastinal lymph node
metastasis before beginning chemoradiotherapy underwent
contralateral mediastinal lymph node resection (R3). In all, 19
patients had complete tumour resection with microscopically
negative margins. In one patient, residual tumour remained
microscopically at the resected margin after surgery. Pathological
downstaging was obtained in 14 patients (64%) and pathological
CR (no viable tumour cells in surgical specimens) was achieved in
five of those 14 patients (23%), the latter five of whom were
determined to have obtained PR by CT scan after induction
therapy.
Postoperative treatment
Among 20 patients undergoing surgical resection, 12 received no
postoperative chemotherapy or radiotherapy until disease pro-
gression. Six patients received postoperative chemotherapy con-
sisting of cisplatin and docetaxel, of whom four had two treatment
courses and two had one course because of toxicity (haemothorax
and diarrhoea in one patient each). One patient whose tumour was
not downstaged underwent further chemoradiotherapy comprising
two courses of cisplatin and docetaxel with concurrent thoracic
irradiation at a dose of 20Gy. Another patient, whose tumour
could not be completely resected, underwent bronchial artery
infusion of cisplatin, mitomycin C and vindesine with concurrent
thoracic irradiation at a dose of 20Gy. Thus, two patients of 22
received a total radiation dose of 60Gy.
Postoperative complications
The major postoperative complication was pulmonary toxicity.
One patient receiving 60Gy radiotherapy developed haemothorax
during postoperative chemotherapy. He was successfully managed
by thoracic tube drainage and was alive without recurrence at the
time of this report. Two patients had massive pleural effusions and
were successfully treated by tube drainage and pleural adhesion
therapy. Six patients experienced radiation pneumonitis (grade 2
in four patients and grade 3 in two) and were treated with
prednisolone. These toxicities were reversible.
Survival and pattern of relapse
At a median follow-up time of 32 months, seven of 22 patients have
had disease relapse. Of those seven patients, six died of disease
progression and one developed solitary brain metastasis and is still
alive. Progression of local tumour was observed in only two of the
six patients who died of cancer. The initial failure sites in the other
four patients were supraclavicular lymph node, para-aortic lymph
node, lung and lumbar spine in one patient each. A total of 15
patients are currently alive with no evidence of recurrent disease.
The 3-year overall and progression-free survival rates were 66 and
61% in 22 enrolled patients (Figure 1), 68 and 63% in 20 patients
who had surgical resection (Figure 2) and 93 and 74% in 14
patients who achieved downstaging of disease (Figure 3), respec-
tively. Five patients achieving pathological CR are currently alive,
although one has developed a solitary brain metastasis.
DISCUSSION
The objective of this study was to investigate the feasibility and
effectiveness of an induction chemoradiotherapy regimen consist-
ing of cisplatin, docetaxel and concurrent thoracic radiation
followed by surgery in patients with LA-NSCLC. Results confirmed
that this combined modality treatment was well tolerated. In other
recent reports of induction chemoradiotherapy followed by
surgery, the frequencies of treatment-related deaths were approxi-
mately 2% during induction therapy and between 4 and 7.5% after
surgery (Albain et al, 1995; Choi et al, 1997; Eberhardt et al, 1998;
Thomas et al, 1999). Therefore, it is notable that none of the
Table 1 Patient characteristics
No. of patients
No. of patients evaluated 22
Median age in years (range) 60 (30–73)
Sex
Male 15
Female 7
ECOG PS
01 1
11 1
Histology
Adenocarcinoma 11
Squamous cell carcinoma 11
Stage of disease
IIIA 14
T1N2M0 3
T2N2M0 7
T3N2M0 4
IIIB 8
T4N0M0 2
T4N1M0 1
T4N2M0 4
T3N3M0 1
ECOG¼Eastern Corporative Oncology Group; PS¼performance status.
Table 2 Toxicity of induction therapy (n¼22)
Grade
1 2 3 4 % of toxicities Xgrade 3
Leukopenia 2 6 10 3 59.1
Neutropenia 2 5 9 4 59.1
Anaemia 10 7 1 0 4.5
Thrombocytopenia 9 0 0 0 0
Nausea/vomiting 13 3 2 0 9.1
Diarrhoea 1 3 1 0 4.5
Constipation 0 0 0 1 4.5
Hepatic 8 2 0 0 0
Renal 3 0 0 0 0
Cardiac 0 0 0 1 4.5
Pulmonary 0 0 0 0 0
Oesophagitis 5 5 1 0 4.5
Allergy 0 0 0 1 4.5
Toxicity was assessed and graded using NCI common toxicity criteria (National
Cancer Institute Common Toxicity Criteria, version 2.0, 1998).
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related deaths during induction therapy or after surgery. In the
present study, the major toxicities of induction therapy, which
included leukopenia, congestive heart failure, paralytic ileus and
anaphylactic reaction to docetaxel, were manageable with standard
approaches. The main postoperative toxicities were pulmonary
complications such as haemothorax, massive pleural effusion and
pneumonitis, which were also successfully managed by standard
treatment.
Efficacy results after induction chemoradiotherapy were good,
with 73% of patients responding and a 3-year survival rate of 66%.
These findings are superior to those achieved in other studies in
patients with LA-NSCLC. For example, 3-year survival rates of 27%
for stage IIIA and 24% for stage IIIB patients were reported by
Albain et al, 37% by Choi et al and 35% for stage IIIA and 26% for
stage IIIB patients by Thomas et al (Albain et al, 1995; Choi et al,
1997; Thomas et al, 1999).
To improve local control, we adopted concurrent chemora-
diotherapy as induction therapy. In the 1990s, a few randomised
trials reported a survival advantage with induction chemotherapy
followed by surgery, compared to surgery alone in patients with
LA-NSCLC (Rosell et al, 1994; Roth et al, 1994). We also previously
reported that induction chemotherapy with cisplatin and irinote-
can was effective in 15 patients with LA-NSCLC, having
pathologically confirmed mediastinal metastases (Date et al,
2002). The 3-year disease-free and overall survival rates were 24
and 40%, respectively, which were considered encouraging.
However, pathological downstaging was obtained in only two
patients (13%) and pathological CR in one (7%). Furthermore,
initial disease relapse occurred at the local site in half of the
patients who had disease relapse (Date et al, 2002). These results
suggested that methods to achieve better local control were needed
to improve the overall outcome for patients with LA-NSCLC.
Based on these findings, the study reported herein used
induction chemoradiotherapy followed by surgery in attempts to
improve the local tumour control. This approach resulted in
downstaging of disease in 59% of the patients, which is similar to
the result (67%) reported by Choi et al (Choi et al, 1997; Date et al,
2002), and significantly better than that in our previous study
(13%, P¼0.007). The pathological CR rate of 23% in the present
study seemed to be improved in comparison with results of our
previous study (7%, P¼0.40) and Choi et al (10%), and
comparable to those of Eberhardt et al (26%) and Thomas et al
(18%) (Choi et al, 1997; Eberhardt et al, 1998; Thomas et al, 1999;
Date et al, 2002). Moreover, local recurrence developed in only two
(29%) of seven relapsed patients. Overall, these results indicate
that considerably good local control can be achieved by using
concurrent chemoradiotherapy as induction.
Several other factors may have contributed to the positive
findings in this study. First, in an attempt to treat distant
micrometastases, we used a two-drug combination of cisplatin plus
docetaxel– one of the most active regimens for advanced NSCLC
(Schiller et al, 2002). Cisplatin, the key drug in the treatment of
NSCLC (Le Chevalier et al, 1999), has potent radiosensitising
effects (DeWit, 1987), and docetaxel, a new active drug for NSCLC
(Creane et al, 1999), also is a radiosensitising agent (Caffo, 2001).
We thus considered that cisplatin plus docetaxel would be an
excellent regimen to incorporate in concurrent chemoradiotherapy
for LA-NSCLC. We previously reported that combined modality
therapy using cisplatin and docetaxel with concurrent thoracic
irradiation was feasible and effective in patients with unresectable
LA-NSCLC (Kiura et al, 2003). The regimen achieved good control
of local tumour and also of distant metastases. In previous studies
of induction chemoradiotherapy, cisplatin-based regimens that
included older agents such as etoposide, vinblastine, or vindesine
were frequently used as induction chemotherapy (Albain et al,
1995; Choi et al, 1997; Eberhardt et al, 1998; Thomas et al, 1999).
However, recent randomised trials showed cisplatin-based combi-
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Figure 1 Overall and disease-free survival curves for 22 enrolled
patients. Estimated 3-year survival and disease-free survival rates were 66
and 61%, respectively.
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Figure 2 Overall and disease-free survival curves for 20 patients who
underwent surgical resection. Estimated 3-year survival and disease-free
survival rates were 68 and 63%, respectively.
0
20
40
60
80
100
05 0 100 150 200 250 300
weeks
%
Figure 3 Overall and disease-free survival curves for 14 patients who
achieved pathological downstaging of disease. Estimated 3-year survival and
disease-free survival rates were 93 and 74%, respectively.
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paclitaxel, and vinorelbine, which were more effective than older
cisplatin-based regimens in patients with advanced NSCLC (Le
Chevalier et al, 1994; Bonomi et al, 2000; Kubota et al, 2002). These
findings thus support the use of a cisplatin plus docetaxel
combination in chemoradiotherapy for LA-NSCLC.
A second factor to consider, regarding the positive results in this
study, is that the administration of both cisplatin and docetaxel
was fractionated, that is, given on days 1, 8, 29 and 36. This
schedule increased the opportunities for simultaneous adminis-
tration of chemotherapy and radiotherapy, and may thus have
increased the radiosensitising effects of chemotherapy. Further-
more, fractionated drug administration may increase chemother-
apy dose intensity. In the present study, the projected dose
intensity of both cisplatin and docetaxel was 20mgm
 2week
 1.I n
actuality, 18mgm
 2week
 1 of cisplatin and 17mgm
 2week
 1 of
docetaxel was administered despite th use of concurrent thoracic
irradiation. These doses are almost equal to those used for
patients with advanced NSCLC, who are not receiving thoracic
irradiation.
Third, although hyperfractionated radiotherapy has been the
preferred approach in recent trials of preoperative chemora-
diotherapy (Choi et al, 1997; Eberhardt et al, 1998; Thomas et al,
1999), results from a recent large-scale randomised trial in LA-
NSCLC showed no superiority of hyperfractionation over standard
fractionation (Curran et al, 2003). Thus, we used standard
fractionation in the study reported herein, which allowed safe
delivery of sufficient radiation doses, while avoiding severe
radiation-induced oesophagitis or pneumonitis.
In conclusion, combined modality treatment consisting of
induction therapy with cisplatin, docetaxel and concurrent
thoracic irradiation followed by surgery is feasible and effective
in patients with LA-NSCLC. A large-scale randomised trial is
warranted to confirm these promising results.
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